

Form PTO-1449

NOV 28 2001

U.S. Department of Commerce  
Patent and Trademark Office

Sheet 1 of 1

Atty. Docket No.  
65019-DC-PCT-US/JPW/AJM/NFMSerial No.  
09/921,937INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants  
Marc Feldmann et al.Filing Date  
August 3, 2001Group 1644  
Not yet known

## U.S. PATENT DOCUMENTS

Examiner Initial								Date	Name	Class	Subclass	Filing Date if Appropriate
26		6	0	1	5	5	5	7	01/18/00	Tobinick et al.		
		6	1	9	0	6	9	1	02/20/01	Mak		
		6	1	7	7	0	7	7	01/23/01	Tobinick		
		5	7	9	5	9	6	7	08/18/98	Aggarwal et al.		
		5	9	5	8	4	1	3	09/28/99	Anagnostopulos et al.		
		5	6	5	6	2	7	2	08/12/97	Le et al.		
		5	7	4	1	4	8	8	04/21/98	Feldmann et al.		
		5	6	9	8	1	9	5	12/16/97	Le et al.		
		5	9	1	9	4	5	2	07/06/99	Le et al.		
		5	3	1	7	0	1	9	05/31/94	Bender et al.		
		5	6	7	2	3	4	7	09/30/97	Aggarwal et al.		

## FOREIGN PATENT DOCUMENTS

									Date	Country	Class	Subclass	Translation	
													Yes	No
		WO	0	0	5	0	0	7	9	08/31/00	PCT			
		WO	8	9	0	8	4	6	0	09/21/89	PCT			
		WO	9	2	0	8	4	7	4	05/29/92	PCT			
		WO	9	2	0	7	5	8	5	05/14/92	PCT			
		WO	9	2	1	6	5	5	3	10/01/92	PCT			
		WO	9	5	0	9	6	5	2	04/13/95	PCT			
		WO	9	6	3	3	2	0	4	10/24/96	PCT			
		WO	9	8	2	4	4	6	3	06/11/98	PCT			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Barrera, P., et al., "Effects of a Weekly Dosis of Methotrexate on IL-1 TNF and IL-6 in patients with Rheumatoid Arthritis," <i>Cytokine</i> , 3 (5) :504, Abstract 330 (1991).
		Bologna, C., and Sany, J., "Association des Traitements de Fond dans la Polyarthrite Rhumatoide," <i>Presse Med.</i> , 25:876-878 (1996).
26		Borigini, M.J., and Paulus, H.E., "Combination Therapy," <i>Baillière's Clin. Rheum.</i> , 9 (4) :689-710 (1995).

EXAMINER

PILIP GUNGE

DATE CONSIDERED

2/13/01

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Marc Feldmann et al.  
Serial No.: 09/921,937  
Filed: August 3, 2001  
Exhibit A

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark Office

ATTY. DOCKET NO.

65019-DC-PCT-US/JPW/AJM/NFM

SERIAL NO.

09/921,937

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

Marc Feldmann et al.,

FILING DATE

August 3, 2001

GROUP ART

UNIT 1644

Not yet known

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Mr	Brahn, E. et al., "Effects of Tumor Necrosis Factor and Combination Cyclosporine A/Methotrexate Therapy on Collagen Arthritis," <i>Arthritis &amp; Rheumatism</i> , 32 (Suppl. 4) :S133 (1992), Abstract D42.
	Breedveld, F., et al., "Anti-CD4 Antibodies in Rheumatoid Arthritis", <i>Clinical and Experimental Rheumatology</i> , 10 (4) :325-326 (1992).
	Brennan, F., et al., "Inhibitory Effect on TNF $\alpha$ Antibodies on Synovial Cell Interleukin-1 Prouction in Rheumatoid Arthritis," <i>The Lancet</i> , 2 (8657) 244-247 (1989).
	Brennan, F., et al., "TNF $\alpha$ -a Pivotal Role in Rheumatoid in Rheumatoid Arthritis?," <i>British J. Rheumatology</i> , 31 (5) :293-298 (1992).
	Butler, D.M., et al., "Modulation of Proinflammatory Cytokine Release in Rheumatoid Synovial Membrane Cell Cultures. Comparison of Monoclonal Anti TNF- $\alpha$ Antibody with the Interleukin-1 Receptor Antagonist," <i>Eur. Cytokine Netw.</i> , 6 (4) :225-230 (1995).
	Choy, E.H.S., et al., "Therapeutic Monoclonal Antibodies," <i>British J. Rheumatology</i> , 34:707-715 (1995).
	Cohen, S., et al., "Comparison of the Safety and Efficacy of Cyclosporine-A and Methotrexate in Refractory Rheumatoid Arthritis: A Randomized, Multi-Centered Placebo-Controlled Trial," <i>Rev. Esp. Rheumatol.</i> , 20 Suppl. 1:148 (1993), Abstract 318.
	Debets, R., et al., "Cytokine Antagonists and their Potential Therapeutic Use," <i>Immunology Today</i> , 15: 455-458 (1994).
	Elliott, M.J. et al., "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to TNF- $\alpha$ Safety, Clinical Efficacy and Control of the Acute Phase Response," <i>Cell. Biochemistry, Supplement</i> , 0 (17B) :145 (1993); Abstract EZ405.
	Elliott, M.J. et al., "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to TNF $\alpha$ " <i>Rev. Esp. Reumatol</i> , 20 Suppl. 1:148 (1993): Abstract 320.
	Elliott, M.J., et al., "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to Tumor Necrosis Factor $\alpha$ ," <i>Arth. Rheum.</i> , 36 (12) :1681-1690 (1993).
	Elliott, M.J., et al., "Randomised Double-Blind Comparison of Chimeric Monoclonal Antibody to Tumor Necrosis Factor $\alpha$ (cA2) Versus Placebo in Rheimatoid Arthritis," <i>The Lancet</i> 344:1105-1110 (1994).
	Elliott, M.J., et al., "Repeated Therapy with Monoclonal Antibody to Tumor Necrosis Factor $\alpha$ (cA2) in Patients with Rheumatoid Arthritis," <i>The Lancet</i> 344:1125-1127 (1994).
	Hervé, P., et al., "Phase I-II Trial of a Monoclonal Anti-Tumor Necrosis Factor $\alpha$ Antibody for the Treatment of Refractory Severe Acute Graft-Versus-Host Disease," <i>Blood</i> , 79:3362-3368 (1992).
	Horneff, G., et al., "Elevated Levels of Circulating Tumor Necrosis Factor- $\alpha$ , Interferon- $\gamma$ , and Interleukin-2 in Systemic Reactions Induced by Anti-CD4 Therapy in Patients with Rheumatoid Arthritis," <i>Cytokine</i> , 3 (3) :266-247 (1991).
	Horneff, G., et al., "Treatment of Rheumatoid Arthritis with an Anti-CD4 Monoclonal Antibody," <i>Arthritis &amp; Rheumatism</i> , 34 (2):129-140 (1991).
	Kalden, J.R., and Manger, B., "Biologic Agents in the Treatment of Inflammatory Rheumatic Diseases," <i>Curr. Opin. Rheum.</i> 7:191-197 (1995).
	Kalden, J.R., and Manger, B., "Biologic Agents in the Treatment of Inflammatory Rheumatic Diseases," <i>Curr. Opin. Rheum.</i> , 9:206-212 (1997).
	Kavanaugh, A., et al., "Anti-TNF- $\alpha$ Monoclonal Antibody (mAb) Treatment of Rheumatoid Arthritis (RA) Patients With Active Disease On Methotrexate (MTX); Results of a Double-Blind, Placebo Controlled Multicenter Trial," <i>Arth. Rheum.</i> , 39 (Suppl. 9) :18-22 (October 1996), Abstract 575.
	Kozarek, R.A., et al., "Methotrexate Induces Clinical and Histologic Remission in Patients with Refractory Inflammatory Bowel Disease," <i>Ann. Int. Med.</i> , 110:353-356 (1989).

D. H. P. L. M. A. S.

2/12/01

Form PTO-1449 NOV 2 8 2001 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. 65019-DC-PCT-US/JPW/AJM/NFM	SERIAL NO. 09/921,937
		APPLICANT Marc Feldmann et al.	RECEIVED NOV 3 0 2001 GROUP ART UNIT 1644 Not yet known
		FILING DATE August 3, 2001	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)			
do		Maini, R.N., et al., "Clinical Response of Rheumatoid Arthritis (RA) to Anti-TNF Monoclonal Antibody (mab) is Related to Administered Dose and Persistence of Circulating Antibody," <i>Arth. Rheum. Supplement</i> , 38 (9) :S186 (1995); Abstract 200.	
		Maini, R.N., "The Role of Cytokines in Rheumatoid Arthritis," <i>J. Royal College of Physicians of London</i> , 30 (4) :344-35 (1996).	
		Manual of Medical Therapeutics, 25 <sup>th</sup> Edition, Orian et al, (editors), Dept. of Medicine, Washington University, St. Louis, MO, Pages 308-309 (1986).	
		Markowitz, J., et al., "Immunology of Inflammatory Bowel Disease: Summary of the Proceedings of the Subcommittee on Immunosuppressive Use in IBD," <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 12 (4) :411-423 (1991).	
		Natanson, C. et al., "Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis," <i>Ann. Int. Med.</i> , 120 (9) :771-783 (1994).	
		Pascalis, L., et al., "Longterm Efficacy and Toxicity of Combined Cyclosporine A-Steroid-Methotrexate Treatment in Rheumatoid Arthritis," <i>Rev. Esp. Rheumatol.</i> , 20 Suppl. 1:148 (1993), Abstract 319.	
		Paul, W.E., ed., <i>Fundamental Immunology</i> , 3 <sup>rd</sup> edition (NY: Raven Press) page 242 (1993).	
		Paul, W.E., ed., "Tumor Necrosis Factor," <i>In Fundamental Immunology</i> , 3 <sup>rd</sup> edition (NY:Raven Press), pages 807-812 (1993).	
		Racadot, E., "Immunological Follow-up of 17 Patients with Rheumatoid Arthritis Treated <i>in vivo</i> with an Anti-T CD4+ Monoclonal Antibody (B-F5)," <i>Clinical and Experimental Rheumatology</i> , 10:365-374 (1992).	
		Ralph, P., "Clinical and Preclinical Studies Presented at the Keystone Symposium on Arthritis, Related Diseases, and Cytokines," <i>Lymphokine and Cytokine Research</i> , 12 (4) :261-263 (1993).	
		Rankin, E.C.C., et al., "The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis," <i>British J. Rheumatology</i> , 34:334-342 (1995).	
		Schact, E., "Gegenwärtige und Zukünftige Therapiestrategien der Rheumatoiden Arthritis (RA)," ["The Current and Future Therapy Strategies of Rheumatoid Arthritis (RA)"] , <i>Zeitschrift für Rheumatologie</i> , 52 (6) :365-382 (1993).	
		Steinbruchel, D., et al., "Monoclonal Antibody Treatment (anti-CD4 and anti-interleukin-2 receptor) Combined with Cyclosporin A has a Positive but not Simple Dose-Dependent Effect on Rat Renal Allograft Survival," <i>Scandinavian J. Immunol.</i> , 34 (5) :627-633 (1991).	
		Van Der Lubbe, P.A., et al., "A Randomized, Double-Blind, Placebo-Controlled Study of CD4 Monoclonal Antibody Therapy in Early Rheumatoid Arthritis," <i>Arth. Rheum.</i> , 38 (8) :1097-1106 (1995).	
		Van Dullemen, H.M., et al., "Treatment of Crohn's Disease with Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)," <i>Gastroenterology</i> , 109 (1) :129-135 (1995).	
		Watts, R.A., and Isaacs, J.D., "Immunotherapy of Rheumatoid Arthritis," <i>Annals Rheumatic Diseases</i> , 51 :577-579 (1992).	
		Williams, R.O., et al., "Successful Therapy of Collagen-Induced Arthritis with TNF Receptor-IgG Fusion Protein and Combination with Anti-CD4," <i>Immunology</i> , 84:433-439 (March 1995).	
		Williams, R.O., et al., "Synergy Between Anti-CD4 and Anti-Tumor Necrosis Factor in the Amelioration of Established Collagen-Induced Arthritis," <i>Proc. Natl. Acad. Sci. USA</i> 91:2762-2766 (1994).	
EXAMINER		DATE CONSIDERED	
PHILIP GANGE 4/13/01			

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
65019-DC-PCT-USSerial No.  
09/921,937INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Applicants: Marc Feldmann et al.

Filing Date

August 3, 2001

Group

JUN 23 2003

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Harris, et al. (1993) Tibtech 11:42-44;Herzog, C., et al. (1987) Lancet 2(8573):1461-1462 (Exhibit 15); ✓Hozzof, et al. (1987) Lancet 11:1461-1462;Kahan, B.D. (1992) Curr. Opin. Immunol. 4:553-560 (Exhibit 16); ✓Littman, B.H., et al. (1995) Arthritis Rheum. 38:29-37 (Exhibit 17); ✓Maini, R.N. (1996) J. Royal College of Physicians of London 30(4):344-351;Matsumiya, G., et al. (1996) Transplant Proceed. 28(2):751-753 (Exhibit 18); ✓Moreland, L.W., et al. (1995) Arthritis Rheum. 38:1581-1588 (Exhibit 19); ✓Moreland, L.W., et al. (1996) J. Rheumatol. (Supplemental 44) 23:78-83 (Exhibit 20); ✓Piguet, et al. (1992) Immunology 77:510-514;Qin, S., et al. (1987) Eur. J. Immunol. 17:1159-1165 (Exhibit 21); ✓Richardson, C., et al. (1995) Br. J. Clin. Prac. 49:135-139 (Exhibit 22); ✓Sander, O., et al. (1995) Arthritis Rheum. 38:S266 (Abstract 678) (Exhibit 23); ✓Sosman, J.A., et al. (1993) J. Pediatric Hematol. Oncol. 15(2):185-195 (Exhibit 24); ✓Stein, C.M., et al. (1994) Arthritis Rheum. 37:S252 (Exhibit 25); ✓Strober, et al. (1990) Immunol. Reviews 118:233-255;Stuart, et al. (1986) Laboratory Investigation 34:1-13 (Exhibit 26); ✓Thorbecke, et al. (1992) Proc. Natl. Acad. Sci. USA 85:7375-7379;Waldmann, T.A. (1991) Science 252:1657-1662;Weinblatt, M.E., et al. (1994) Arthritis Rheum. 37:1492-1498 (Exhibit 27); and ✓

Decision on Appeal, issued March 21, 2003, for U.S. Serial No. 09/109,458, filed June 8, 1998 (Exhibit 28); ✓

EXAMINER

PHILIP GANDIA

DATE CONSIDERED

2/13/04

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
JUN 25 2003  
TECH CENTER 1600/2900